Lapides Asset Management’s Core Laboratories CLB Stock Holding History

Lapides Asset Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-27,800	Closed	-$2.74M	–	87
2017 Q3	$2.74M	Buy	27,800 +300	+1%	+$29.1K	0.56%	55
2017 Q2	$2.79M	Sell	27,500 -3,800	-12%	-$410K	0.54%	52
2017 Q1	$3.62M	Hold	31,300	–	–	0.68%	46
2016 Q4	$3.76M	Hold	31,300	–	–	0.67%	46
2016 Q3	$3.52M	Hold	31,300	–	–	0.6%	46
2016 Q2	$3.88M	Hold	31,300	–	–	0.72%	42
2016 Q1	$3.52M	Sell	31,300 -300	-0.9%	-$31.2K	0.63%	42
2015 Q4	$3.44M	Sell	31,600 -3,600	-10%	-$412K	0.6%	55
2015 Q3	$3.51M	Buy	35,200 +2,700	+8%	+$294K	0.6%	60
2015 Q2	$3.71M	Hold	32,500	–	–	0.59%	58
2015 Q1	$3.4M	Buy	+32,500	New	+$3.46M	0.56%	57

Other funds holding CLB

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Lapides Asset Management's CLB Position: Q4 2017 in Review

Lapides Asset Management sold out of Core Laboratories (CLB) in Q4 2017, closing a stake of 27,800 shares — an estimated $2.74M sold.

Lapides Asset Management first reported a position in CLB in Q1 2015 and held it in 11 quarters. The position peaked at $3.88M in Q2 2016. 356 funds tracked by Wall St. Rank hold CLB as of Q4 2017.

Lapides Asset Management reported no remaining Core Laboratories position as of Q4 2017 after selling out during the quarter.
Lapides Asset Management sold 27,800 Core Laboratories shares in Q4 2017, an estimated $2.74M.
Lapides Asset Management first reported a position in Core Laboratories in Q1 2015 and held it in 11 quarters.
Lapides Asset Management's Core Laboratories position peaked at $3.88M in Q2 2016.
356 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2017.

Based on Lapides Asset Management's 13F filing for Q4 2017, filed 8 Feb 2018.